Geron Appoints Dr. Eid to Boost Leadership in Blood Cancer Treatments

Geron Corporation Strengthens Leadership to Advance Blood Cancer Treatments

Geron Corporation, a biopharmaceutical company dedicated to innovating therapies for blood cancers, announces the appointment of Dr. Joseph Eid as Executive Vice President of Research and Development, effective November 11, 2024. This strategic move aims to enhance Geron’s research capabilities and bolster the commercial success of its first-in-class telomerase inhibitor, RYTELO™ (imetelstat), which has already received approval for treating lower-risk myelodysplastic syndromes (LR-MDS) in the United States. With a wealth of experience in medical affairs, clinical development, and drug life-cycle management, Dr. Eid is expected to play a pivotal role in guiding Geron’s R&D organization and fostering innovative strategies to bring transformative treatments to patients.

Dr. Eid brings over 20 years of expertise in the biopharmaceutical industry, having previously held significant leadership roles at companies such as Dragonfly Therapeutics and Merck. His track record includes instrumental contributions to the development of KEYTRUDA®, one of the most successful oncology drugs in recent years. With a background that spans clinical oncology drug development at Roche and senior leadership at Bristol Myers Squibb, where he led a global medical affairs team, Dr. Eid’s appointment is seen as a critical step in reinforcing Geron’s leadership in hematology and oncology. Geron’s CEO, Dr. John A. Scarlett, expresses enthusiasm about Dr. Eid's extensive experience, indicating that his leadership will enhance collaboration within the company and support its mission to alter the trajectory of blood cancer treatment.

The company’s ongoing commitment to advancing therapies is further exemplified by its participation in the upcoming Stifel 2024 Healthcare Conference in New York City on November 18, 2024. Geron’s management team will engage in a fireside chat, which will be accessible through a webcast on the company’s website, allowing for a broad audience to learn more about its innovative approaches and initiatives in blood cancer treatment. This engagement not only highlights Geron’s dedication to transparency and communication with the investment community but also underscores its focus on transforming the lives of patients battling blood cancers through groundbreaking therapies.

In addition to these developments, Geron is actively conducting a pivotal Phase 3 clinical trial of imetelstat for patients with JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF) and exploring its potential application in other hematologic malignancies. The mechanism of action of imetelstat, which inhibits elevated telomerase activity in malignant stem and progenitor cells, positions it as a promising treatment option for patients in need of effective therapies. For more information about Geron’s initiatives and updates, interested parties are encouraged to visit their website or follow the company on LinkedIn.